Mabqi was established in 2017 by a team of 6 scientists and serial entrepreneurs. The company’s origins lie in the research carried out by Pierre Martineau’s Inserm team at the Montpellier Cancer Research Institute (IRCM).
The company was laureate of i-Lab 2018 (French deep-tech innovation competition) and won the Innovation & International awards at Les Inn’Ovations 2022.
Since its inception, the company is committed to improving human health and fostering the development of next-generation antibody therapies.
Based on its core’s technology and scientific teams, the company develops a strong portfolio of proprietary, first-in-class and best-in-class antibodies with high therapeutic potential in oncology. A few of these antibodies are now available for partnerships and licensing opportunities.
In addition, the company makes its proprietary fully human synthetic libraries and know-how available to the biopharmaceutical industry for the discovery and development of therapeutic antibodies through partnerships and collaborative agreements.
Mabqi merges two concepts:
Together, Mabqi embodies an innovative and dynamic company dedicated to the research and development of therapeutic-diagnostic antibodies for human and animal health.
Our team brings together management excellence, experienced industry profiles and world-class scientific expertise.
Mabqi headquarters and laboratories are located in the Euromedicine biopark, Montpellier, France. Our laboratories and offices cover an area of 800 m2.
